Entheon Biomedical Corp.
ENBI
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -100.00% | -100.00% |
| SG&A Expenses | 1.65% | -4.41% | -41.29% | -61.84% | -75.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.65% | -4.41% | -41.29% | -62.00% | -76.79% |
| Operating Income | -1.65% | -39.82% | -5.76% | 32.17% | 67.18% |
| Income Before Tax | -2.76% | -34.68% | -4.81% | 35.28% | -201.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.76% | -34.68% | -4.81% | 35.28% | -201.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.76% | -34.68% | -4.81% | 94.98% | 93.86% |
| EBIT | -1.65% | -39.82% | -5.76% | 32.17% | 67.18% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 39.75% | 13.71% | 17.29% | 95.63% | 94.20% |
| Normalized Basic EPS | 41.86% | 15.70% | 22.40% | -14.06% | 59.43% |
| EPS Diluted | 43.95% | 26.16% | 28.51% | 95.66% | 93.79% |
| Normalized Diluted EPS | 41.86% | 15.70% | 22.40% | -14.06% | 59.43% |
| Average Basic Shares Outstanding | 74.05% | 56.78% | 30.90% | 18.45% | 5.97% |
| Average Diluted Shares Outstanding | 74.05% | 56.78% | 30.90% | 18.45% | 5.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |